Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series.

Cardiooncology · 2021 · PMC8008661 · PMID 33785062

Europe PMC DOI

hedged sentence

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

a nonsignificant trendp = 0.089so close (0.05 < p ≤ 0.1)

There was a nonsignificant trend toward higher admission and peak troponins (0.7 vs. 0.2 ng/ml p = 0.089 and 1.0 vs. 0.2 ng/mL p = 0.13, respectively) in the infliximab group.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.